A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
Phase 4
Completed
- Conditions
- Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 281
- Registration Number
- NCT02130024
- Locations
- 🇦🇺
Novartis Investigative Site, Subiaco, Western Australia, Australia
Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma
Phase 3
Withdrawn
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02127697
Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary DiseaseCOPD
- Interventions
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02125734
- Locations
- 🇩🇪
Novartis Investigative Site, Warendorf, Germany
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Phase 2
Completed
- Conditions
- Chronic Iron Overload Due to Transfusion-dependant Anemias
- Interventions
- Drug: Defearisox film-coated tablet
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 173
- Registration Number
- NCT02125877
- Locations
- 🇺🇸
Lurie Children's Hospital of Chicago Onc Dept, Chicago, Illinois, United States
🇺🇸Children's Hospital of Orange County Onc Dept, Orange, California, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 139
- Registration Number
- NCT02124772
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT02123199
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02116803
- Locations
- 🇪🇸
Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain
Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
Phase 3
Terminated
- Conditions
- Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT02115386
- Locations
- 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 78
- Registration Number
- NCT02115113
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Phase 3
Terminated
- Conditions
- Philidelphia Positive Chronic Myeloid Leukaemia
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT02108951
- Locations
- 🇦🇺
Novartis Investigative Site, Nedlands, Western Australia, Australia